Having trouble accessing articles? Reset your cache.

ANA598: Additional Phase II data

In an ongoing, double-blind, placebo-controlled, U.S. Phase II trial in 95 patients, all 6 patients who received 200 mg ANA598 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus

Read the full 300 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE